Thompson Siegel & Walmsley’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-312
| Closed | -$69K | – | 524 |
|
|
2023
Q4 | $69K | Hold |
312
| – | – | ﹤0.01% | 408 |
|
|
2023
Q3 | $70K | Hold |
312
| – | – | ﹤0.01% | 405 |
|
|
2023
Q2 | $69K | Sell |
312
-17
| -5% | -$3.77K | ﹤0.01% | 414 |
|
|
2023
Q1 | $74K | Sell |
329
-189
| -36% | -$46.6K | ﹤0.01% | 412 |
|
|
2022
Q4 | $144K | Sell |
518
-103,347
| -100% | -$26.1M | ﹤0.01% | 366 |
|
|
2022
Q3 | $21.7M | Sell |
103,865
-25,664
| -20% | -$5.74M | 0.38% | 79 |
|
|
2022
Q2 | $30.5M | Sell |
129,529
-9,058
| -7% | -$1.84M | 0.49% | 69 |
|
|
2022
Q1 | $24.9M | Buy |
138,587
+5,048
| +4% | +$962K | 0.35% | 82 |
|
|
2021
Q4 | $28.9M | Sell |
133,539
-22,373
| -14% | -$4.39M | 0.4% | 80 |
|
|
2021
Q3 | $28.8M | Sell |
155,912
-119,590
| -43% | -$23.6M | 0.42% | 74 |
|
|
2021
Q2 | $49.4M | Sell |
275,502
-82,982
| -23% | -$15.8M | 0.68% | 53 |
|
|
2021
Q1 | $60M | Sell |
358,484
-13,369
| -4% | -$2.23M | 0.86% | 45 |
|
|
2020
Q4 | $56.4M | Sell |
371,853
-57,746
| -13% | -$7.58M | 0.9% | 42 |
|
|
2020
Q3 | $43.4M | Sell |
429,599
-14,428
| -3% | -$1.58M | 0.84% | 43 |
|
|
2020
Q2 | $53.7M | Sell |
444,027
-167,453
| -27% | -$18.8M | 1.08% | 35 |
|
|
2020
Q1 | $58M | Sell |
611,480
-225,834
| -27% | -$21.5M | 1.38% | 17 |
|
|
2019
Q4 | $73.8M | Sell |
837,314
-6,948
| -0.8% | -$611K | 1.13% | 35 |
|
|
2019
Q3 | $67.3M | Sell |
844,262
-20,942
| -2% | -$1.69M | 1.07% | 37 |
|
|
2019
Q2 | $67.5M | Buy |
865,204
+437,094
| +102% | +$40.9M | 0.97% | 40 |
|
|
2019
Q1 | $50.2M | Sell |
428,110
-22,027
| -5% | -$2.57M | 0.7% | 61 |
|
|
2018
Q4 | $49M | Sell |
450,137
-62,290
| -12% | -$7.22M | 0.77% | 59 |
|
|
2018
Q3 | $65.5M | Sell |
512,427
-46,680
| -8% | -$5.77M | 0.84% | 52 |
|
|
2018
Q2 | $63.3M | Buy |
559,107
+16,638
| +3% | +$1.83M | 0.82% | 48 |
|
|
2018
Q1 | $61M | Sell |
542,469
-43,885
| -7% | -$5.58M | 0.75% | 47 |
|
|
2017
Q4 | $86.8M | Sell |
586,354
-4,028
| -0.7% | -$512K | 1.03% | 34 |
|
|
2017
Q3 | $69.2M | Buy |
590,382
+9,271
| +2% | +$1.18M | 0.83% | 41 |
|
|
2017
Q2 | $75.4M | Buy |
581,111
+92,093
| +19% | +$11.5M | 0.89% | 38 |
|
|
2017
Q1 | $66.2M | Sell |
489,018
-26,644
| -5% | -$4.04M | 0.78% | 42 |
|
|
2016
Q4 | $74M | Sell |
515,662
-18,905
| -4% | -$2.41M | 0.97% | 26 |
|
|
2016
Q3 | $63.1M | Sell |
534,567
-33,219
| -6% | -$3.99M | 0.98% | 19 |
|
|
2016
Q2 | $60.1M | Buy |
567,786
+331,476
| +140% | +$37M | 0.95% | 23 |
|
|
2016
Q1 | $26.3M | Buy |
236,310
+231,736
| +5,066% | +$29.3M | 0.43% | 85 |
|
|
2015
Q4 | $716K | Sell |
4,574
-686
| -13% | -$99.9K | 0.01% | 296 |
|
|
2015
Q3 | $690K | Sell |
5,260
-4,860
| -48% | -$779K | 0.01% | 308 |
|
|
2015
Q2 | $1.76M | Sell |
10,120
-20
| -0.2% | -$3.6K | 0.03% | 256 |
|
|
2015
Q1 | $1.75M | Sell |
10,140
-4,145
| -29% | -$632K | 0.03% | 251 |
|
|
2014
Q4 | $1.85M | Sell |
14,285
-132,296
| -90% | -$17M | 0.04% | 257 |
|
|
2014
Q3 | $18.9M | Buy |
146,581
+146,331
| +58,532% | +$15.1M | 0.38% | 94 |
|
|
2014
Q2 | $22K | Sell |
250
-9,400
| -97% | -$904K | ﹤0.01% | 538 |
|
|
2014
Q1 | $907K | Sell |
9,650
-2,718
| -22% | -$278K | 0.02% | 284 |
|
|
2013
Q4 | $1.4M | Sell |
12,368
-401,032
| -97% | -$36.2M | 0.03% | 268 |
|
|
2013
Q3 | $32.6M | Sell |
413,400
-164,516
| -28% | -$12M | 0.71% | 27 |
|
|
2013
Q2 | $38M | Buy |
+577,916
| New | +$37.2M | 0.82% | 9 |
|
Other funds holding UTHR
ACA
Thompson Siegel & Walmsley's UTHR Position: Q1 2024 in Review
Thompson Siegel & Walmsley sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 312 shares — an estimated $69K sold.
Thompson Siegel & Walmsley first reported a position in UTHR in Q2 2013 and held it in 43 quarters. The position peaked at $86.8M in Q4 2017. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.
- Thompson Siegel & Walmsley reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
- Thompson Siegel & Walmsley sold 312 United Therapeutics shares in Q1 2024, an estimated $69K.
- Thompson Siegel & Walmsley first reported a position in United Therapeutics in Q2 2013 and held it in 43 quarters.
- Thompson Siegel & Walmsley's United Therapeutics position peaked at $86.8M in Q4 2017.
- 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.
Based on Thompson Siegel & Walmsley's 13F filing for Q1 2024, filed 9 May 2024.